Concepedia
Statistics
Publications
4
Citations
54
H-Index
Active since
2012
Affiliations
Sarah Cannon(Current)
Oncology Hematology Care
Tennessee Oncology
Florida Hospital Cancer Institute
Florida Cancer Specialists & Research Institute
Douglas B. Flora is an author at Sarah Cannon specializing in cancer immunotherapy, phase ii investigation, and oncology pharmacotherapy.
Publications per year
2012–2017
A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers
Johanna C. Bendell, Ahmed Zakari, Evan Lang et al. · Cancer Investigation · 2016 · 17 citations
Medicine, Oncology, Pharmacology +15
Open‐label, single‐arm, phase <scp>II</scp> study of enzastaurin in patients with follicular lymphoma
Lee Schwartzberg, Róbert Hermann, Ian W. Flinn et al. · British Journal of Haematology · 2014 · 15 citations
Medicine, Oncology, Pharmacology +13
Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET).
Irfan Firdaus, Kent C. Shih, Ahmed Zakari et al. · Journal of Clinical Oncology · 2012 · 12 citations
Medicine, Pharmacology, Pharmacotherapy +15
Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma
Ian W. Flinn, Dana S. Thompson, Ralph V. Boccia et al. · British Journal of Haematology · 2017 · 10 citations · Full text
Medicine, Oncology, Pharmacotherapy +8
1–4 of 4